All 150 Peptides Ranked

A synthetic peptide derived from a protein found in gastric juice, studied for its regenerative and protective properties across multiple tissue types.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management, representing one of the most significant pharmaceutical developments in obesity treatment.

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and weight management, demonstrating even greater weight loss efficacy than semaglutide in clinical trials.

A synthetic version of a naturally occurring peptide involved in tissue repair, cell migration, and anti-inflammatory processes, widely used in research and veterinary applications.

A synthetic growth hormone-releasing hormone (GHRH) analog that stimulates pituitary growth hormone secretion, available in two forms with different duration profiles.

A selective growth hormone secretagogue peptide that stimulates GH release with minimal impact on cortisol and prolactin, considered one of the milder GH-releasing peptides.

A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women, acting through central nervous system pathways rather than vascular mechanisms.

A naturally occurring copper-binding tripeptide with broad regenerative properties, extensively used in skincare and studied for wound healing, anti-aging, and tissue remodeling.

A synthetic melanocortin peptide that stimulates melanogenesis for skin tanning, also noted for effects on sexual arousal and appetite suppression.

A modified fragment of human growth hormone specifically studied for fat metabolism, designed to retain lipolytic properties without the growth-promoting or diabetogenic effects of full GH.

A synthetic analog of growth hormone-releasing hormone (GHRH) that was previously FDA-approved for diagnosing and treating growth hormone deficiency in children.

An FDA-approved GHRH analog specifically indicated for reducing excess abdominal fat in HIV-associated lipodystrophy, also studied for broader metabolic and cognitive benefits.

One of the first synthetic growth hormone secretagogues discovered, known for potent GH release but also significant appetite stimulation through ghrelin receptor activation.

A synthetic growth hormone secretagogue considered more potent than GHRP-6 with less appetite stimulation, approved in Japan for diagnostic evaluation of GH deficiency.

The most potent synthetic growth hormone secretagogue in the GHRP family, known for robust GH release and cardioprotective properties, but also notable for causing desensitization with prolonged use.

A synthetic tetrapeptide studied for its potential to activate telomerase, the enzyme responsible for maintaining telomere length, based on decades of research by Russian gerontologist Vladimir Khavinson.

A synthetic analog of the naturally occurring immunomodulatory peptide tuftsin, developed in Russia as an anxiolytic and nootropic agent with a unique mechanism distinct from benzodiazepines.

A synthetic analog of ACTH(4-10) developed in Russia as a neuroprotective and nootropic agent, approved there for stroke recovery, cognitive disorders, and peptic ulcer treatment.

The only human cathelicidin antimicrobial peptide, playing a critical role in innate immune defense against bacteria, viruses, and fungi, with additional immunomodulatory and wound healing properties.

A tripeptide fragment of alpha-melanocyte-stimulating hormone with potent anti-inflammatory properties, studied for inflammatory bowel conditions and skin inflammation.

A peptide bioregulator derived from thymus gland extract, studied in Russia for immune restoration and anti-aging effects, particularly in elderly populations with declining thymic function.

A naturally occurring nonapeptide first isolated from rabbit brain tissue during induced sleep, studied for its role in sleep regulation, stress adaptation, and neuroendocrine modulation.

A truncated form of the naturally occurring hormone kisspeptin that plays a master regulatory role in reproductive function, studied for fertility applications and hormonal assessment.

A splice variant of IGF-1 produced in response to mechanical stress on muscle tissue, studied for its role in muscle repair and satellite cell activation.

A modified form of IGF-1 with enhanced potency and a significantly longer half-life, widely studied for muscle growth and cell proliferation effects.

A naturally occurring glycoprotein that inhibits myostatin and activin, studied for its potential to promote muscle growth beyond normal genetic limits.

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management, predating semaglutide as the first GLP-1 agonist approved specifically for obesity.

A naturally occurring neuropeptide hormone with established roles in childbirth, lactation, and social bonding, increasingly studied for autism, anxiety, and social cognition.

The naturally occurring incretin hormone that regulates blood sugar and appetite, serving as the biological template for the revolutionary GLP-1 receptor agonist drug class.

A mitochondrial-derived peptide that acts as an exercise mimetic, regulating metabolic homeostasis with potential applications in aging, obesity, and metabolic disease.

A mitochondrial-derived peptide with cytoprotective properties, studied for its potential to protect against age-related diseases including Alzheimer's, cardiovascular disease, and metabolic disorders.

A mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane, studied for its ability to improve mitochondrial function in aging and disease states.

A naturally occurring 28-amino acid neuropeptide with potent anti-inflammatory, vasodilatory, and immunoregulatory properties, studied for chronic inflammatory response syndrome and respiratory conditions.

A synthetic peptide derivative of angiotensin IV reported to be millions of times more potent than BDNF at promoting new synaptic connections, studied for cognitive enhancement and neurodegenerative diseases.

A critical coenzyme found in every living cell that plays essential roles in energy metabolism, DNA repair, and cellular signaling, with declining levels associated with aging and age-related diseases.

A complex of neurotrophic peptides derived from porcine brain tissue, approved in many countries for stroke, traumatic brain injury, and dementia, with extensive clinical use particularly in Europe and Asia.

A synthetic octapeptide designed to reduce facial wrinkles by mimicking the mechanism of botulinum toxin, inhibiting the SNARE complex involved in muscle contraction at the neuromuscular junction.

One of the first and most commercially successful cosmetic peptides, designed to reduce wrinkles by partially inhibiting neurotransmitter release at the facial neuromuscular junction.

A lipopeptide that stimulates collagen production by mimicking the body's natural collagen-building signals, one of the most proven and widely used anti-aging cosmetic peptides.

Bioactive peptide fragments derived from collagen protein hydrolysis, among the most widely consumed supplements globally for skin, joint, and bone health support.

A tripeptide antioxidant produced in every cell of the body, considered the master antioxidant for its central role in detoxification, immune function, and protection against oxidative stress.

A triple-acting agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, representing the next evolution in incretin-based obesity treatment with the highest weight loss observed in clinical trials to date.

A dual GLP-1 and glucagon receptor agonist being developed for obesity and NASH, offering a different dual-agonist approach from tirzepatide by targeting glucagon rather than GIP alongside GLP-1.

A non-peptide, orally available GLP-1 receptor agonist that could revolutionize obesity and diabetes treatment by eliminating the need for injections, in advanced clinical development by Eli Lilly.

A combination therapy pairing the amylin analog cagrilintide with semaglutide, designed to provide complementary appetite-suppressing mechanisms for enhanced weight loss.

A general class of peptides consisting of 15 amino acids, most notably associated with BPC-157, studied for broad tissue-protective and regenerative properties.

A soluble form of the activin type IIB receptor that acts as a myostatin trap, initially developed for Duchenne muscular dystrophy before clinical development was halted due to safety concerns.

An orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release, notable for being a non-peptide small molecule rather than an injectable peptide.

A synthetic heptapeptide derived from the sortilin propeptide that acts as a TREK-1 potassium channel blocker, studied as a rapid-acting antidepressant with fewer side effects than traditional antidepressants.

A naturally occurring thymic peptide that is one of the most clinically validated immune-modulating peptides, approved in multiple countries for hepatitis B/C and as an immune system adjuvant.

A lipopeptide used in cosmetic formulations to stimulate collagen production and reduce visible signs of skin aging through extracellular matrix remodeling.

A naturally occurring dipeptide with potent antioxidant and anti-glycation properties found in high concentrations in muscle and brain tissue, studied for its potential anti-aging effects.

A nonapeptide hormone produced by the thymus gland that requires zinc for biological activity, playing a critical role in T-cell maturation and immune system regulation.

A synthetic form of the naturally occurring gonadotropin-releasing hormone used diagnostically and therapeutically to evaluate and stimulate pituitary gonadotropin function.

A potent synthetic GnRH agonist used in the treatment of prostate cancer, endometriosis, uterine fibroids, and precocious puberty through sustained suppression of sex hormone production.

An FDA-approved melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder in premenopausal women, acting through central nervous system pathways rather than vascular mechanisms.

A synthetic GnRH agonist analog primarily used in veterinary medicine and reproductive research, with applications in controlled ovarian stimulation and assisted reproduction protocols.

A potent synthetic GnRH agonist primarily used in veterinary medicine as a subcutaneous implant for reproductive control in animals, with limited investigational use in humans.

One of the most widely prescribed GnRH agonists globally, FDA-approved for prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and as part of assisted reproduction protocols.

A potent synthetic GnRH agonist administered as a nasal spray, primarily used for the treatment of endometriosis and central precocious puberty.

A synthetic GnRH agonist available in intranasal and injectable formulations, widely used in Europe for prostate cancer, endometriosis, and assisted reproduction protocols.

A potent synthetic GnRH agonist unique for its subcutaneous implant delivery system providing continuous drug release for 12 months, used for prostate cancer and central precocious puberty.

The first GnRH antagonist approved for prostate cancer treatment, providing immediate testosterone suppression without the initial hormonal flare seen with GnRH agonists.

A next-generation GnRH antagonist approved for advanced prostate cancer, providing immediate testosterone suppression without flare while offering a favorable safety profile compared to earlier GnRH antagonists.

A synthetic somatostatin analog that mimics the hormone's inhibitory effects on growth hormone, insulin, and glucagon secretion, widely used for acromegaly and neuroendocrine tumors.

A long-acting somatostatin analog administered as a deep subcutaneous injection every 4 weeks, used for acromegaly and gastroenteropancreatic neuroendocrine tumors with demonstrated antiproliferative effects.

A novel multireceptor-targeted somatostatin analog with unique affinity for SSTR5, approved for Cushing's disease and acromegaly when other somatostatin analogs are ineffective.

A synthetic somatostatin analog investigated for the treatment of variceal bleeding and neuroendocrine tumors, with a receptor binding profile similar to octreotide.

The first GLP-1 receptor agonist approved for type 2 diabetes, derived from a compound found in Gila monster venom, available in both twice-daily and once-weekly formulations.

A once-daily GLP-1 receptor agonist approved for type 2 diabetes, notable for its potent effects on slowing gastric emptying and reducing postprandial glucose excursions.

A once-weekly GLP-1 receptor agonist featuring a large molecular weight fusion protein design, approved for type 2 diabetes with demonstrated cardiovascular benefits.

A once-weekly GLP-1 receptor agonist featuring an albumin fusion design, which demonstrated cardiovascular benefits in the HARMONY Outcomes trial but was voluntarily withdrawn from the market due to commercial factors.

A synthetic analog of the pancreatic hormone amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes, acting to slow gastric emptying, suppress glucagon, and promote satiety.

A synthetic peptide derived from cone snail venom that selectively blocks N-type calcium channels, delivered intrathecally for the management of severe chronic pain refractory to other therapies.

A cyclic heptapeptide derived from rattlesnake venom that inhibits platelet aggregation by blocking the glycoprotein IIb/IIIa receptor, used in acute coronary syndromes and percutaneous coronary interventions.

A synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor, widely used as an anticoagulant during percutaneous coronary interventions as an alternative to heparin.

A synthetic analog of the antidiuretic hormone vasopressin with enhanced antidiuretic potency and minimal vasopressor activity, used for diabetes insipidus, bedwetting, hemophilia A, and von Willebrand disease.

A synthetic vasopressin analog that selectively targets V1 receptors to reduce splanchnic blood flow, FDA-approved for the treatment of hepatorenal syndrome with rapid reduction in renal failure.

A peptide hormone that inhibits osteoclast activity to reduce bone resorption, used for the treatment of osteoporosis, Paget's disease, and hypercalcemia, available as an injectable and nasal spray.

A recombinant form of the first 34 amino acids of human parathyroid hormone that stimulates new bone formation, FDA-approved as the first anabolic agent for severe osteoporosis treatment.

A synthetic analog of parathyroid hormone-related protein (PTHrP) that stimulates bone formation with a potentially improved balance of bone formation over resorption compared to teriparatide.

A 36-amino acid synthetic peptide that prevents HIV-1 entry into host cells by blocking the viral fusion machinery, representing the first approved HIV fusion inhibitor.

A peptidomimetic hepatitis C virus NS3/4A protease inhibitor that was among the first direct-acting antivirals for HCV, now largely supplanted by newer, more effective combination regimens.

A peptidomimetic HCV NS3/4A protease inhibitor that, along with boceprevir, initiated the direct-acting antiviral era in hepatitis C treatment, now superseded by more effective and tolerable regimens.

A synthetic decapeptide that selectively antagonizes bradykinin B2 receptors, FDA-approved for the treatment of acute hereditary angioedema attacks by blocking the inflammatory mediator responsible for tissue swelling.

A peptibody (peptide-Fc fusion protein) thrombopoietin receptor agonist that stimulates platelet production, FDA-approved for chronic immune thrombocytopenia in patients with insufficient response to other treatments.

A synthetic eel calcitonin derivative used primarily in Japan and some Asian countries for the treatment of osteoporosis and pain associated with osteoporotic fractures.

A synthetic peptide identical to the calcitonin hormone produced by salmon, approximately 40-50 times more potent than human calcitonin, used for osteoporosis, Paget's disease, and hypercalcemia.

A synthetic peptide consisting of the first 24 amino acids of adrenocorticotropic hormone (ACTH), used as a diagnostic agent in the ACTH stimulation test to evaluate adrenal cortex function.

A synthetic pentapeptide analog of gastrin used diagnostically to stimulate gastric acid secretion and calcitonin release for the evaluation of gastric function and medullary thyroid carcinoma screening.

The first hormone ever discovered, secretin is a 27-amino acid peptide used diagnostically to evaluate pancreatic exocrine function, gastrinoma, and to facilitate MRCP imaging.

A synthetic C-terminal octapeptide of cholecystokinin used diagnostically to stimulate gallbladder contraction, pancreatic secretion, and to assess gallbladder ejection fraction in hepatobiliary imaging.

A synthetic tripeptide identical to the hypothalamic thyrotropin-releasing hormone, historically used in the TRH stimulation test to evaluate pituitary TSH reserve and diagnose thyroid disorders.

A synthetic form of ovine corticotropin-releasing hormone used diagnostically to differentiate between pituitary and ectopic sources of ACTH in the evaluation of Cushing's syndrome.

A synthetic 24-amino acid ACTH analog formulated as a depot preparation for therapeutic use, primarily prescribed for infantile spasms and as an anti-inflammatory agent for conditions responsive to corticosteroids.

A 29-amino acid peptide hormone produced by pancreatic alpha cells that raises blood glucose levels, used as emergency treatment for severe hypoglycemia and as a diagnostic agent in radiology and gastroenterology.

A synthetic form of the naturally occurring octapeptide hormone that regulates blood pressure through potent vasoconstriction, FDA-approved as a vasopressor for the treatment of refractory distributive shock.

A recombinant form of human B-type natriuretic peptide (BNP) that promotes vasodilation and natriuresis, approved for the treatment of acute decompensated heart failure with dyspnea at rest.

A synthetic peptide oxytocin receptor antagonist used to delay preterm labor by inhibiting uterine contractions, approved in Europe but not in the United States.

A long-acting synthetic oxytocin analog used to prevent postpartum hemorrhage following cesarean delivery, with a duration of action approximately 4-10 times longer than oxytocin.

A lipopeptide used in cosmetic formulations to reduce inflammation-related skin aging by suppressing interleukin-6 secretion, often combined with Palmitoyl Oligopeptide.

A cosmetic peptide designed to reduce under-eye puffiness and dark circles by decreasing vascular permeability and fluid accumulation in periorbital tissue.

A naturally occurring copper-binding tripeptide with extensive research supporting its roles in wound healing, skin remodeling, collagen synthesis, and anti-inflammatory activity.

A lipopeptide used in anti-aging skincare that mimics collagen fragments to stimulate new collagen production and extracellular matrix repair in the dermis.

A lipopeptide that mimics elastin fragments to stimulate elastin production and improve skin elasticity, targeting loss of firmness associated with aging.

A lipopeptide used in cosmetic products to promote eyelash and eyebrow growth by stimulating keratin production in hair follicles.

A biotinylated peptide that combines the hair-supporting properties of biotin with a tripeptide sequence to strengthen hair follicles and reduce hair thinning.

A biomimetic peptide that stimulates hair follicle dermal papilla cells to promote hair growth, often used as part of the Capixyl hair restoration complex.

A biotin-peptide conjugate used in hair care products to improve hair anchoring, stimulate growth, and reduce hair shedding through follicle-level nourishment.

A recombinant form of human epidermal growth factor used in skincare and wound healing to stimulate cell proliferation, migration, and tissue regeneration.

A recombinant oligopeptide with growth factor-like activity used in skincare to promote skin cell regeneration, wound repair, and anti-aging benefits.

An FDA-approved guanylate cyclase-C receptor agonist peptide used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

An FDA-approved guanylate cyclase-C agonist structurally similar to uroguanylin, used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation.

A naturally occurring 43-amino acid peptide found in soybeans and other seeds, studied for its antioxidant, anti-inflammatory, and potential cancer-preventive properties.

An antimicrobial peptide derived from the milk protein lactoferrin, studied for its broad-spectrum activity against bacteria, fungi, viruses, and parasites, as well as immunomodulatory properties.

A naturally occurring antimicrobial peptide produced by Lactococcus lactis, widely used as a food preservative and studied for therapeutic applications against drug-resistant bacteria.

A cyclic lipopeptide antibiotic used as a last-resort treatment for multidrug-resistant Gram-negative bacterial infections, particularly those caused by Pseudomonas, Acinetobacter, and Klebsiella species.

A cyclic polypeptide antibiotic produced by Bacillus subtilis, widely used topically for prevention and treatment of minor skin infections and as a component of common first-aid ointments.

A group of antimicrobial peptides produced by Bacillus brevis that form ion channels in bacterial membranes, used topically for treating bacterial eye and skin infections.

A cyclic lipopeptide antibiotic approved for treating serious Gram-positive bacterial infections, including MRSA, with a unique calcium-dependent membrane depolarization mechanism.

A glycopeptide antibiotic that has been a cornerstone treatment for serious Gram-positive infections including MRSA for decades, working by inhibiting bacterial cell wall synthesis.

A polymyxin-class lipopeptide antibiotic used as a last-resort treatment for multidrug-resistant Gram-negative infections, particularly carbapenem-resistant Enterobacterales.

A naturally occurring peptide hormone that inhibits the release of growth hormone, insulin, glucagon, and other hormones, with therapeutic applications in managing hormonal hypersecretion and gastrointestinal bleeding.

An 11-amino acid neuropeptide involved in pain signaling, inflammation, and mood regulation, acting primarily through the neurokinin-1 (NK-1) receptor in the central and peripheral nervous systems.

A 36-amino acid neuropeptide that is one of the most abundant peptides in the central nervous system, involved in appetite regulation, stress responses, anxiety, and cardiovascular function.

A peptide hormone produced in the duodenum that stimulates gallbladder contraction, pancreatic enzyme secretion, and acts as a satiety signal, with additional roles as a neurotransmitter in the brain.

A peptide hormone produced by G-cells of the stomach that stimulates gastric acid secretion, with important roles in gastrointestinal physiology and as a diagnostic marker for gastric disorders.

A 22-amino acid peptide hormone that regulates gastrointestinal motility, particularly the migrating motor complex during fasting, and serves as the basis for prokinetic drug development.

A 28-amino acid peptide hormone primarily produced by the stomach that stimulates appetite, growth hormone release, and energy metabolism, often called the 'hunger hormone.'

Peptide fragments derived from the satiety hormone leptin, studied for their roles in appetite suppression, metabolic regulation, and potential therapeutic applications in obesity research.

Peptide fragments and mimetics derived from adiponectin, an adipose tissue-secreted hormone with insulin-sensitizing, anti-inflammatory, and cardioprotective properties, investigated for metabolic disease applications.

An endogenous peptide ligand for the APJ receptor with potent cardiovascular effects including vasodilation, positive inotropy, and fluid homeostasis, investigated for heart failure treatment.

A cleaved fragment of the membrane protein FNDC5, released from skeletal muscle during exercise, that promotes browning of white adipose tissue and has been linked to numerous metabolic benefits.

Peptides designed to block myostatin (GDF-8), a negative regulator of muscle growth, investigated for treating muscle-wasting conditions and enhancing muscle mass.

A naturally occurring glycoprotein that inhibits myostatin and activin signaling, studied for muscle growth promotion and investigated as a potential therapeutic for muscle-wasting disorders.

A synthetic peptide containing the first 24 amino acids of adrenocorticotropic hormone, used as a diagnostic agent to test adrenal gland function and cortisol production capacity.

A 31-amino acid endogenous opioid neuropeptide produced by the pituitary gland and hypothalamus, known for its role in pain modulation, euphoria, and stress response regulation.

A five-amino acid endogenous opioid peptide that was among the first endorphins discovered, with roles in pain modulation, immune regulation, and cell growth control.

A 17-amino acid endogenous opioid peptide that acts primarily on kappa-opioid receptors, involved in pain processing, stress responses, and mood regulation with distinct dysphoric properties.

A nine-amino acid peptide generated by the kallikrein-kinin system that causes vasodilation, increases vascular permeability, and mediates inflammation and pain signaling.

A seven-amino acid peptide of the renin-angiotensin system that acts through the Mas receptor to produce vasodilation, anti-inflammatory, and cardioprotective effects, counterbalancing the harmful effects of angiotensin II.

A 21-amino acid peptide produced by vascular endothelial cells that is the most potent known endogenous vasoconstrictor, implicated in hypertension, heart failure, and pulmonary arterial hypertension.

A 52-amino acid vasodilatory peptide originally isolated from adrenal medulla tumors, with potent cardiovascular, renal, and anti-inflammatory effects, investigated as both a biomarker and therapeutic agent.

A cyclic peptide originally discovered in fish that is the most potent known mammalian vasoconstrictor, implicated in cardiovascular disease, heart failure, and pulmonary hypertension.

A 30-amino acid neuropeptide widely distributed in the nervous system, involved in pain modulation, feeding behavior, cognition, mood regulation, and neuroendocrine function.

A 33-amino acid neuropeptide produced by hypothalamic neurons that promotes wakefulness, arousal, and appetite, with deficiency causing narcolepsy type 1.

A 28-amino acid neuropeptide co-produced with orexin-A that selectively activates the OX2 receptor, involved in sleep-wake regulation, arousal, and metabolic homeostasis.

A highly conserved neuropeptide with potent neuroprotective, neurotrophic, and anti-inflammatory properties, investigated for neurological disorders and increasingly recognized in migraine pathophysiology.

A 37-amino acid neuropeptide that is one of the most potent endogenous vasodilators and a key mediator of migraine, serving as the target for a revolutionary new class of migraine therapeutics.

A 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells that regulates post-meal glucose levels, with a synthetic analog (pramlintide) approved for diabetes treatment.